In recent trading session, Mineralys Therapeutics Inc (NASDAQ:MLYS) saw 0.56 million shares changing hands at last check today with its beta currently measuring 2.20. Company’s recent per share price level of $9.30 trading at $0.17 or 1.86% at last check today assigns it a market valuation of $461.75M. That most recent trading price of MLYS’s stock is at a discount of -81.83% from its 52-week high price of $16.91 and is indicating a premium of 37.1% from its 52-week low price of $5.85. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.2 million shares which gives us an average trading volume of 214.48K if we extend that period to 3-months.
For Mineralys Therapeutics Inc (MLYS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.82 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Mineralys Therapeutics Inc (NASDAQ:MLYS) trade information
Upright in the green today for gaining 1.86%, in the last five days MLYS remained trading in the red while hitting it’s week-highest on Tuesday, 08/13/24 when the stock touched $9.30 price level, adding 21.72% to its value on the day. Mineralys Therapeutics Inc’s shares saw a change of 8.14% in year-to-date performance and have moved -16.74% in past 5-day. Mineralys Therapeutics Inc (NASDAQ:MLYS) showed a performance of -33.05% in past 30-days. Number of shares sold short was 1.51 million shares which calculate 6.85 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 30 to the stock, which implies a rise of 69.0% to its recent value today. Analysts have been projecting 30 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would drop -222.58% in reaching the projected high whereas dropping to the targeted low would mean a loss of -222.58% for stock’s current value.
Mineralys Therapeutics Inc (MLYS) estimates and forecasts
Statistics highlight that Mineralys Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -36.04% of value to its shares in past 6 months, showing an annual growth rate of -46.73% while that of industry is 17.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.
Mineralys Therapeutics Inc (NASDAQ:MLYS)’s Major holders
Insiders are in possession of 2.56% of company’s total shares while institution are holding 101.01 percent of that, with stock having share float percentage of 103.66%. Investors also watch the number of corporate investors in a company very closely, which is 101.01% institutions for Mineralys Therapeutics Inc that are currently holding shares of the company.
On the other hand, iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024, the former fund manager was holding 688.68 shares of worth $6.46 million or 1.39% of the total outstanding shares. The later fund manager was in possession of 659.55 shares on Mar 31, 2024, making its stake of worth around $6.19 million in the company or a holder of 1.33% of company’s stock.
